الفهرس 
List of contents
List of AbbreviationsOnly 14 pages are availabe for public view
 |  | from | 140 |  |  |
| | | from | 140 | | |
Abstract
Graves’ disease patients undergoing RAIT exhibit varying timelines for hypothyroidism onset. This retrospective study mainly investigated several factors influencing this timing and their implications for treatment outcomes In our study 303 patients with Graves’ disease treated with RAI from 2013-2022 at two Egyptian hospitals were included. Data collected included demographics, laboratory values, thyroid imaging, RAI doses, and outcomes. Patients were followed for ≥1 year toassess success rate of RAIT and factors influencing hypothyroidism onsetAt the end of one year around 79.5% of the individuals developed hypothyroidism while 12.5% continued to experience hyperthyroidism. The onset of hypothyroidism occurred earlier in those with thyroid volume (≤75.5Cm3), lower weight (≤84.7g), uptake (≤18.8%), and higher RAI dose/volume (≥0.1022mCi/mL) (p<0.001). Additionally, there was a correlation between the presence of Anti-TPO antibodies and faster development of hypothyroidism compared to those without these antibodies (2.9 vs 8.9 months, p=0.001). When considering factors in analysis it was found that anti TPO antibodies were the only independent predictor, for developing hypothyroidism (HR 30.47 p<0.001). Additionally, thyroid volume and uptake independently predicted successful treatment outcomes (p<0.05).